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Frontotemporal dementia (FTD) is a neurodegenerative disorder associated with a poor 
prognosis and a substantial reduction in quality of life. The rate of misdiagnosis of FTD is 
very high, with patients often waiting for years without a firm diagnosis. This study 
investigates the current state of the misdiagnosis of FTD using a novel artificial intelligence-
based algorithm. 
PATIENTS & METHODS  
An artificial intelligence algorithm has been developed to retrospectively analyse the patient 
journeys of 47 individuals diagnosed with FTD (age range 52-80). The algorithm analysed 
the efficiency of patient pathways by utilizing a reward signal of ‒1 to +1 to assess the 
symptoms, imaging techniques, and clinical judgement in both behavioural and language 
variants of the disease.  
RESULTS  
On average, every patient was subjected to 4.93 investigations, of which 67.4% were 
radiological scans. From first presentation it took on average 939 days for a firm diagnosis. 
The mean time between appointments was 204 days, and the average patient had their 
diagnosis altered 7.37 times during their journey. The algorithm proposed improvements by 
evaluating the interventions that resulted in a decreased reward signal to both the individual 
and the population as a whole.  
CONCLUSIONS 
The study proves that the algorithm can efficiently guide clinical practice and improve the 
accuracy of the diagnosis of FTD whilst making the process of auditing faster and more 
economically viable.  
 
KEYWORDS: frontotemporal dementia, cognitive disorders and dementia, imaging, 
computational neurology, artificial intelligence 
 





Frontotemporal dementia (FTD) is a neurodegenerative disorder associated with a poor 
prognosis and dramatic reduction in quality of life [1]. FTD accounts for up to 20% of young-
onset dementias [2] and despite recent advances in imaging techniques, codification of 
diagnostic criteria and epidemiological studies, the rate of misdiagnosis is still very high, 
particularly early on in the disease [3,4]. Because symptoms can mimic various other 
neurological and psychiatric diseases (as indeed shown in the ‘Results’ section of the present 
paper), FTD patients are often subjected to a number of different investigations, clinic visits, 
scans, and biochemical tests before the correct diagnosis can be made [5]. 
New treatments are emerging for the different variants of dementias, and thus an early and 
accurate diagnosis of dementia subtype is increasingly more important [6–8]. An accurate 
panel of diagnostic tests could also minimize the distress for the patient, sparing unnecessary 
investigations and misdiagnoses they currently experience [9]. This will also reduce 
associated healthcare costs by avoiding inappropriate investigations and treatments. 
 
1.1 The variability and inaccuracy of the diagnostic criteria 
FTD presents itself in two major variants: behavioural and linguistic (non-fluent and 
semantic), which complicates the task of standardizing the criteria. The histopathological 
examinations is heterogeneous in FTD cases as different symptoms have been associated with 
various different neuropathologies and genotypes [10].  
There are no universally accepted criteria for the diagnosis of the FTD. The Neary 
criteria [11] recognize all three clinical phenotypes of FTD and incorporate them into a 
universal panel. More recently, however, Rascovsky published a more detailed criteria for 
diagnosing behavioural variant FTD [12] according to its likelihood (possible, probable and 
definite). Semantic and non-fluent variants of FTD are usually assessed using the Gorno-
Tempini criteria [13]. Our study reports an analysis for all three groups of criteria, to 
maximize the clinical application of the paper’s findings. 
To enhance the accuracy of these panels, various improvements have been proposed. 
Apraxia examination [14], neuropsychometry [15,16], or amyloid-β 2-42 CSF analysis [17] 
have all been used to better differentiate FTD from other types of dementia. Nevertheless, 
when subjected to confounders such as Alzheimer’s disease or Lewy Body Dementia, the 
criteria reveal a very poor sensitivity for FTD [18,19]. Indeed, our study reports on the most 




Some point to a better use of imaging techniques as a panacea for the problem. 
However, diagnosing FTD from an MRI scan can be very difficult, particularly in the early 
stages of the disease [20,21]. An addition of a multivariate analysis [22] or a PET scan may 
improve the accuracy [23,24], albeit only to a limited extent [25].  
Single positron emission computer tomography (SPECT) emerged as a potentially 
useful tool, as it attempts to directly measure the perfusion of the affected areas (i.e. frontal 
and temporal lobes). However, there is a mixed picture in the literature concerning these 
scans, with their considerable limitations [26,27]. A recent meta-analysis revealed that there 
is currently insufficient evidence to recommend the use of SPECT scans in routine practice 
[28]. EEG may be helpful [29–31] but it is not usually employed in a dementia clinic. 
Another difficulty is that of the disease progression [32]: the symptoms of the FTD 
can vary at different stages of presentation. 
 
1.2 Machine learning and pattern recognition 
The inaccuracies of human perception could potentially be mitigated by the recent 
developments in the field of computational biology. Several studies demonstrated that 
artificial intelligence (AI)-developed methods of imaging analysis and pattern recognition can 
reliably improve the diagnostic accuracy when compared to a human-based assessment (e.g. 
in classification of fractures [33], dermatological assessment [34], or MRI interpretation [35–
39]).  
We have expanded the scope of that analysis to include the entirety of the patient’s 
journey: from the first presentation to neurology services to the final diagnosis of FTD. 
In this paper, we present a result of a retrospective longitudinal AI-powered study of 
patients with FTD diagnosis, assessing the progression of their disease in time, most common 
misdiagnoses, and the reasons for inaccuracies. The study aims to report on the current state 
of the problem and to propose potential improvements in the clinical practice. 
 
2. PATIENTS AND METHODS 
2.1 Participant selection 
The participants were selected from an anonymized database from the Memory Clinic in the 
Brain Centre, Southmead Hospital, Bristol, UK. This is a tertiary referral centre and a major 
university hospital for neurosciences in the South West of England (5.6m population) [40]. 
The main secondary care service, however, is provided within the Bristol metropolitan and 




patient had to have a full diagnosis of any FTD variant. At the time of search, records 
included hospital visits from 2009 to 2017. The selection process is illustrated in Fig. 1. 
 
2.2 Frideswide algorithm set-up 
A total of 47 patient journeys were followed and analysed using the Frideswide AI algorithm 
(FwA) [41]. The input was generated from clinical letters, discharge summaries, request 
sheets and investigation reports available on the hospital’s computer system. The date of 
admission (and the first point on the timeline to be analysed) was set to the first presentation 
with a neurological symptom, be it to the Emergency Department (ED), or via a referral from 
the General Practitioner (GP). The last follow-up was concluded when the patient was given 
a firm diagnosis by a neurologist (Fig. 2). For the secondary analysis of the FTD variants, the 
first point on the timeline was adjusted to the first neurology services encounter: on the ward 
or in clinic, since it would be unlikely for an ED physician or a GP to use criteria-based 
evaluation of the disease. 
 
2.3 Reward assignment 
Amid the healthcare informatics revolution, the “AI” and “machine learning” terms have 
been used in a variety of different situations [42]. For clarity, the FwA is an analytic tool that 
acts as an intelligent agent [43]. It studies the environment composed of the available data 
(clinical information from letters, reports, requests, etc.) in different time frame nodes, each 
healthcare encounter being a different node. It then attempts to achieve the best maximisation 
of the diagnostic efficiency (goal function in AI nomenclature), i.e. so that the patient is 
diagnosed at a minimum time, cost and invasiveness.  
The AI uses the doctor-defined pay-off table to determine the values of different 
decisions it may take. The overall aim is to produce a list of improvements that could achieve 
the most optimal efficiency for the entire hospital. The exact process is described below and 
in Fig 2. 
After the data was imported, each visit to the hospital was represented as a point on 
the timeline, with corresponding symptoms, current differential diagnoses, care plans and 
actions. The appointments were then associated with each other on an action-outcome basis, 
in a chronological order. This data model was then enhanced by adding information about 
diagnostic accuracy, time, cost, and invasiveness of the interventions (Fig.2). 
The utility function [44] of the FwA assigned the BK coefficients to each of the 




whether an outcome was clinically desirable. It translates what a human being would consider 
a good or a bad outcome into a numerical figure that the AI can understand. This way, the AI 
was able to evaluate an association, by having a set of standards and values. Each association 
was assigned a pay-off award in the form of a BK coefficient, which represents an association 
that is desirable clinically on the scale of 1 to -1, from the most to the least desired outcome.  
This was dictated by the following payoff set: {firm diagnosis: 1, ?diagnosis: 0.5, 
very close diagnosis: 0.3, associated diagnosis: 0.25, unknown or entirely different diagnosis: 
–1}. A “?” sign was used to signalize that a diagnosis was not certain at a given point in time. 
This way, the action that resulted in the firm diagnosis of FTD would be ideal (BK=1), and 
the action that resulted in a firm diagnosis of a different disease, e.g. Huntington’s disease 
would be least desirable (BK= – 1) 
The algorithm then attempted to approximate the state of the world [45], i.e. the 
neurology service provided for the patients as analysed in the study, to the ideal overall BK 
coefficient of BK=1.  
To that end, it suggested a number of improvements, which were collected in a matrix. 
An improvement was a FwA-generated suggestion of how the service can be enhanced. In 
this context, an improvement is something that would enhance the diagnostic accuracy. These 
improvements were then tested against their feasibility across the entire population, to see 
whether they would work if they were actually introduced as a routine service element to be 
applied to all patients. 
 
2.4 Improvement analysis and reporting 
If, by removing the negative element from the journey, the entire population were better off 
(overall BK increased), the improvement was deemed significant. If, on the contrary, the 
negative element’s contribution was beneficial to the large sample overall, it was deemed a 
necessary evil, as enough patients in the population benefited from that element to warrant its 
usefulness.  
 
2.5 If it can diagnose, it can misdiagnose 
Some investigations are performed to exclude an alternative diagnosis or to not to miss a 
sinister or less common aetiology. Therefore, to correct for this phenomenon, only 
investigations which at any point reported a diagnosis of FTD were subsequently included in 
the analysis. Those which did not purport to be capable of making that diagnosis were not 





2.6 Natural history of the disease 
A battery of quantitative panels was also performed to assess the state of the FTD population. 
Since the study collected a large number of symptoms, imaging reports and investigations 
results, we have reported on the natural history of the FTD development, as captured during 
various hospital appointments and examinations. 
Notwithstanding the variability of the available diagnostic tools, we have decided to 
evaluate the accuracy of the FTD diagnosis with the most widely used criteria [11]. These 
include measurements of behavioural change, linguistic problems, pattern of social and 
personality changes over time and supportive information from neuropsychometry, EEG, and 
imagining. One point was awarded for every element on the panel (both sections I and II of 
the criteria [11]). 
The patients were then sub-divided into language (both non-fluent primary 
progressive aphasia and semantic form) and behaviour variants of the disease, and further 
assessed using the Raskovsky and Gorno-Tempini criteria, respectively [12,13]. The 
assessment was used to evaluate any differences in care between the two variants and to 
report a natural history of the disease over time. 
Some participants were offered neuropsychometry as well as genetic tests. However, 
because of the computer system set-up, the dates of these appointments cannot be reliably 
established. Nevertheless, they have still been included in the analysis. Their date was set at 
the time of the patient learning about the outcome, which was the date of the next 
appointment. 
 
2.7 Ethical issues 
The project was reviewed and received a favourable ethical opinion from NHS Health 
Research Authority, IRAS project ID: 209781.  
 
2.8 Statistical analysis 
Descriptive statistics were used to summarize the quantitative sections. Overall effect of the 
improvements was calculated in a meta-analysis statistical panel, including z-test for total 
fixed effects, and Cochrane’s Q and I2 tests for heterogeneity. We appreciate that these 
statistical tools are commonly associated with a meta-analysis of studies; in this context, the 
independence assumption is not valid. Thus, the metrics are intended to aid the understanding 




statistically significant, i.e. whether a phenomenon indicated in the results could be explained 
by the data used for its evaluation. The odds ratio (OR) and ANOVA were used in secondary 
analysis of the power of a request form. Unpaired two-tailed t-test was used to evaluate the 




3.1 Quantitative panel 
The demographics, times and a categorized breakdown of symptoms and healthcare services 
received by the patients are presented in Table 1. Before reaching the diagnosis, on average, 
every patient was subjected to 4.93 distinct types of investigations, 67.4% of which were 
radiological scans (CT, MRI, 123I-ioflupane nuclear neuroimaging - DaTscan, and SPECT). 
From presenting to the hospital with a neurological symptom, be it from a GP referral 
or via the emergency department, an average patient waited 939 days (just under 2 years and 
7 months, range 18-2911 ± 758 days) for their firm diagnosis. The mean time between the 
various hospital appointments (including scans) was 204 days (6 months 3 weeks, range 17-
877 ± 150 days). The average patient had their diagnosis of record changed 7.37 times (range 
3-25 ± 4) during their journey. There was no statistical difference between behavioural and 
language variants of FTD in any of these measurements. The full breakdown is displayed in 
Table 1. 
 
3.2 Diagnostic criteria 
Globally, the mean diagnostic Neary score at the first presentation was (out of 24): 0.89 ± 
1.81 (range 0-8), and the mean culminated score at the time of a firm diagnosis was 9.78 ± 
5.72 (range 2-28). The progression of the mean culminated score over the course of hospital 
appointments is illustrated in Fig. 5A, with sensitivities for a clinical diagnosis with different 
cut-off scores is shown in Fig. 5B.  
The most common categories of symptoms are presented with their prevalence on the 
first and subsequent appointments, along with their overall prevalence throughout the journey 
in Fig. 5C. The progression of the disease in behavioural and language variants of the disease 
is illustrated in Fig. 6 and Fig. 7. 
 




Whilst some patients received their initial indication of FTD fairly promptly (in less than 9 
months) after presenting with their symptoms, others were misdiagnosed or undiagnosed for 
a long time (up to 2911 days). Out of the latter group, one pattern of differential diagnosis 
featured a series of confounding diagnoses initially (Fig. 3), and then a narrowing-down 
process leading to the FTD diagnosis.  
The other pattern consisted of a series of negative pivotal points, whereby an 
indicative diagnosis of FTD was removed from consideration and replaced by either a 
confounding diagnosis or lack of any diagnosis at all. The most common change generating a 
negative BK score was a suspicion of the FTD to unknown (18 cases), other types of 
dementia to unknown (11 cases) and a suspicion of FTD into other types of dementia (6 
cases). 
The breakdown of negative and positive BK results of particular interventions is 
presented in Fig. 4. The total time for computing and analysing of the aforementioned data 




Overall, this work shows that the best and most accurate diagnosis of FTD is still made 
clinically. The usefulness of radiological investigations ranged from borderline helpful to 
being a substantial distractor, especially when used not to exclude an alternative diagnosis but 
to confirm the FTD (Fig 4).  
Based on the obtained data, the large waiting times and stress of coming to the 
hospital could have been substantially alleviated if the diagnosis had been made based on 
clinical picture and biochemical blood investigations only, to exclude other diagnoses (i.e. 
organic causes of the symptoms, such as electrolyte imbalance, liver dysfunction, 
autoimmune and paraneoplastic disorders, etc.). 
The benefits of performing the MRI or SPECT scans were demonstrated to be 
outweighed by the costs, time, and distress to the patient, especially in the case of the MR 
imaging. 
It also must be noted that the invasiveness of the scan may subjectively be more 
significant to a patient experiencing FTD-like symptoms, than to a healthy control. 
However, the value of the actual time saved is difficult to establish. Frequently, the 




is done. Furthermore, the progression of the disease in time could be important 
diagnostically, as several neurodegenerative disorders present with distinct natural histories.  
CT scans reported numerous BK=0 neutral scores, as their use was, in many cases, to 
exclude other diagnoses or more acute syndromes. 
 
4.1 Reading letters saves lives 
Interestingly, inability to read the clinical letters was one of the major cause of negative BK 
scores in the diagnostic process of the FTD. Lack of proper familiarization with the current 
patient’s notes resulted in a substantial number of unnecessary referrals and investigations 
that either did not contribute any relevant clinical information or, even worse, distracted from 
the FTD diagnostic pathway.  
One reason for this phenomenon could be a lack of an integrated clinical letter system 
in Southmead Hospital, as indeed is seen in many other hospitals. For instance, Emergency 
Department clinicians may not be aware of clinical letters from the Neurology Department 
and could thus bona fide assume that the current admission is the patient’s first presentation 
with the symptoms. This may be aggravated by the difficulty of obtaining a detailed history 
from a patient with memory and language problems.  
The caregivers of the patient attending the hospital may not have the copies of clinical 
letters at hand. For an assessing physician, the collateral history may offer a limited degree of 
reassurance. Thus, they may be requesting additional scans to confirm the diagnosis of a 
neurodegenerative disorder. We appreciate there may be many further reasons for not being 
able to read the cognitive neurology letters.  
 
4.2 The art and power of a request form 
Whilst the SPECT scan is widely requested for the diagnosis of FTD, the clinical evidence 
for its use is still lacking [28]. This type of investigation was the only FTD-specific non-
clinical benchmark identified in the study and its overall performance was positive, albeit 
with a substantial number of occasions where its negative findings severely delayed the 
diagnosis. 
Secondary analysis of the reports and requests for the SPECT scan revealed a very 
interesting relation: by putting the suspicion of the FTD on the request form, there was an 
OR=5.75 (z=2.101, p=0.036) of receiving a positive report (i.e. one reporting that the scan 
was in keeping with FTD), whereas a negative finding was independent of a request form. 




negative report. There was no difference (F3=0.446; p=0.72) between the groups in terms of 
symptoms or clinically-assessed progression of the disease. 
This may either indicate a confirmation bias in clinicians over-diagnosing the FTD 
after a positive scan or a more diligent scan interpretation prompted by the suggestion on the 
form. 
 
4.3 Towards an accurate diagnosis  
There have been several attempts to assess the sensitivity of the FTD scoring panels in the 
past: 79% [46] and 36.5% [47] were reported for the Neary criteria. These figures would be 
replicated in our study by applying a cut-off point of 5. 
Interestingly, we have been able to demonstrate how the mean culminated score on 
the Neary criteria is changing over time, which allows for the application of a cut-off point 
not only in terms of desired sensitivity (relative to clinical diagnosis), but also within a 
specified timeframe. 
We have, however, deliberately exercised caution in reporting the sensitivity figures, 
as they may not be very reliable in the absence of a gold standard independent of the 
consensus criteria. Specificity was also not available because of ethics constraints on the 
current study, disallowing the inclusion of non-FTD cases.  
Per analogiam, we have refrained from proposing our own adjustments to the 
diagnostic criteria at this stage.  
 
4.4 Concrete problems of AI implementation 
Putting the FwA to a real-life test revealed several phenomena that were not displayed during 
the initial simulation [41] (Fig 2A). Interestingly, these were hypothesized in the landmark AI 
paper before [48] and thus the study is of an immense value to the computer scientists 
exploring this unchartered territory. 
 
4.4.1 Avoiding negative side effects 
Since the model of reality presented to the algorithm differs from the one perceived by the 
consultant, it is difficult to prescribe all the negative side effects [48] that a neurologist would 
have taken for granted, e.g. an acute confusion and slurred speech warrant a CT scan with 
suspected cerebrovascular event. The algorithm, however, perceives it as a deviation from its 
goal and is willing to sacrifice the patient’s health, ignore the stroke, and allow the ischemia 




phenomenon with a supervised learning of these side effects, yet we appreciate that there is a 
vast number of potential negative and positive side effects that are still unaccounted for. 
 
4.4.2 Avoiding reward hacking 
The FwA quickly acquired a skill of evading our intended outcomes. It managed to accelerate 
the process of getting to the reward quicker by generating improvements that would not be 
clinically feasible.  
One of these phenomena was a genius effect, whereby by removing a confounding 
factor, e.g. a test result, the consultant in the latter part of the association appeared to have 
made the diagnosis out of their skill, whereas in fact, they would have been aware of the 
result that was artificially removed. 
We managed to largely eradicate this by introducing more distinct, sometimes 
conflicting dimensions contributing to the BK coefficient. This made the algorithm consider 
several factors when making a decision, a situation similar to the one faced by a clinician.  
We anticipate that further sophistication of the coefficient would not only make the result 
more clinically applicable but will contribute to minimizing the reward hacking. 
 
4.4.3 The scalable oversight and safe exploration 
These problems were avoided by a sheer volume of data which did not require separate 
supervised teaching exercises. Furthermore, the algorithm was not allowed to make decisions 
about the treatment or diagnosis at this stage.  
However, an argument could be put forward that the sandbox simulation omitted the 
unexpected consequences of these decisions. This is inevitable in clinical practice, where a 
great deal of caution must be exercised when trailing the AI systems. We envisage that a slow 
and methodological implementation of the suggestions and a re-audit cycle would be a safe 
approach to this problem, as is in the case of a standard clinical audit. 
 
4.5 The advantage of AI use  
The data analysis and results presented in this report could have been achieved by standard 
statistics and by using auditing methods currently available. However, the AI use offers 
certain advantages. 
First, the superiority of the FwA is in the time saved in performing the analysis. The 
overall process took 24.5 seconds on a standard PC machine (Intel ® Core ™ i7-4790 CPU 




analysed 1,597 clinical findings and 515 clinical decisions, generated 44 hypotheses and 
conducted 249 experiments, where it re-evaluated the patients’ journeys, back to back, to test 
whether a hypothesis is clinically feasible. This volume of data would require considerably 
more time and resources to be analysed by human means. 
Furthermore, a classic audit would usually involve testing a hypothesis that is known 
to the researcher before starting the analysis. The FwA not only has the capacity to test 
multiple hypotheses without a significant increase of time required but can also generate new 
hypotheses on its own. This means that the FwA-generated audit can reveal a clinically 
valuable answer to the question that is not known a priori.  
It is also possible to adapt the FwA for other clinical scenarios e.g. time taken to diagnose 
lung cancer. The same program can perform multiple different analyses across different 
specialties. 
 
4.6 Limitations of the study 
The design of the study was aimed at analysing the FTD population only. Hence, the FwA 
had a limited impact of confounding diagnoses or indeed the journeys whereby the FTD was 
mentioned as a differential and an alternative firm diagnosis was made at the end. Thus, the 
improvements suggested by the algorithm can enhance the sensitivity but not specificity of 
the FTD diagnosis. 
Furthermore, since the firm diagnosis of FTD was made by the consultant, there is a 
limited space to scrutinize the clinical assessment efficacy. To alleviate this, an alternative 
gold standard could be introduced, e.g. a histopathological examination, which would provide 
an independent indicator of accuracy. We appreciate that this can limit the applicability of the 
statistical results; this is a common problem in diseases that cannot be definitely diagnosed 
ante mortem. 
We appreciate that there may be further difference to be elucidated in non-fluent vs. 
semantic variants of the language FTD. However, the study was not powered to investigate 
these in detail and thus the groups were displayed together in the figures and tables. 
Nevertheless, the Gorno-Tempini diagnostic criteria have been applied appropriately to the 
respective variants.  
The study presents the analysis of the population under care of a major neurology 
centre in the South West of England. We appreciate that a multi-centre study is warranted for 




Furthermore, since the FTD incidence is 2.4-4.1 per 100,000 [1], it is difficult to obtain a 
large dataset of patients for the analysis. This is a major limitation in the generalisability of 
the FwA. However, large data requirement can limit many smaller audits in clinical practice. 
This paper can serve as an indication that smaller studies, e.g. on rare diseases or on a small 
population are still feasible.   
 
5. CONCLUSIONS 
Frontotemporal dementia is still a very difficult to diagnose condition. Patients often wait for 
years to receive their diagnosis, and during that time they are subjected to a number of 
potentially distressing and sometimes unnecessary investigations. They are often given 
different disease names to explain their memory and language problems, and each of those is 
associated with a shock and stress of learning about the condition. This comes at a cost to the 
patient’s psychological wellbeing and puts an extra pressure on the already stretched 
healthcare service resources.  
Since FTD is associated with a shorter life expectancy and poorer prognosis than 
more conventional dementias, an accurate and prompt diagnosis is of a paramount 
importance in planning of treatment and making personal life choices by the patient.  
This can be achieved by a constant audit cycle, implementation of improvements in 
diagnostic technique and a repeated evaluation of patient journeys. Normally, that process 
would require extensive amount of effort, funds, and staff hours.  
This study, however, proves that by using an AI-powered algorithm, the process could 
be made more economically viable and could easily produce the results to guide a better 
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